Open Actively Recruiting

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis


Brief Summary

This is a multi-part, randomized, double-blind, placebo-controlled Phase 2 clinical study comparing the safety and efficacy of bezuclastinib (CGT9486) plus best supportive care (BSC) with placebo plus BSC in patients with nonadvanced systemic mastocytosis (NonAdvSM), including indolent systemic mastocytosis and smoldering systemic mastocytosis, whose symptoms are not adequately controlled by BSC. This study will be conducted in three parts. Patients in Parts 1a, 1b and 2 will receive bezuclastinib or placebo, and may roll over onto Part 3 to receive treatment with bezuclastinib.

Primary Purpose
Study Type
Phase 2


Healthy Volunteers
Minimum Age
18 Years
Maximum Age

Key Inclusion Criteria:

  • Diagnosed with 1 of the following diagnoses according to the 2016 World Health Organization (WHO) classification for systemic mastocytosis (SM):
    • Indolent systemic mastocytosis (ISM), including the bone marrow mastocytosis subvariant
    • Smoldering systemic mastocytosis (SSM)
  • Moderate-to-severe symptoms based on a disease-specific PRO and after establishing a stable regimen of at least 2 antimediator therapies over a 14-day eligibility period
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2
  • For patients receiving corticosteroids, the dose must be ≤10 mg/day of prednisone or equivalent

Key Exclusion Criteria:

  • Diagnosed with any of the following WHO SM classifications: bone marrow mastocytosis, advanced systemic mastocytosis including SM with associated hematologic neoplasm, aggressive SM, mast cell leukemia; or mast cell sarcoma
  • Diagnosed with mastocytosis of the skin without systemic involvement
  • Received prior treatment with any targeted KIT inhibitor with the exception of approved agents for the treatment of SM
  • Received prior cytoreductive therapy or investigational agent for <14 days or 5 half- lives of the drug and for cladribine, interferon alpha, pegylated interferon, or antibody therapy <28 days or 5 half-lives of the drug (whichever is longer), before starting screening assessments
  • Received radiotherapy or psoralen and ultraviolet A therapy <14 days before starting screening assessments
  • Received any hematopoietic growth factor support <14 days before starting screening assessments
  • History of clinically significant bleeding event within 30 days before the first dose of study drug or need for therapeutic anticoagulation on study
  • Need for treatment of corticosteroids at >10 mg/day of prednisone or equivalent

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
Other Cancer
Bruck Habtemariam
  • UCLA Westwood
For Providers
For detailed technical eligibility, visit